Lung cancer remains one of the leading causes of cancer-related deaths worldwide, primarily due to late-stage diagnosis. Early detection through systematic screening has proven to significantly improve survival rates, prompting healthcare systems to adopt advanced screening programs. As awareness grows and technology advances, the lung cancer screening market is emerging as a critical segment within global diagnostic and preventive healthcare.

Market Overview

The global lung cancer screening market was valued at USD 2.71 Billion in 2025 and is expected to grow at a strong CAGR of 8.20% during the forecast period, reaching approximately USD 5.96 Billion by 2035. Market growth is largely driven by the increasing prevalence of lung cancer, especially among high-risk populations such as smokers, elderly individuals, and those exposed to environmental pollutants.

Lung cancer screening primarily relies on low-dose computed tomography (LDCT), which has demonstrated higher accuracy in detecting early-stage tumors compared to traditional imaging methods. The growing adoption of LDCT screening programs across developed and developing regions is significantly contributing to market expansion.

Key Growth Drivers

Several factors are accelerating the growth of the lung cancer screening market:

Rising global lung cancer incidence: Increased tobacco use, air pollution, and occupational hazards are expanding the screening population.

Emphasis on early diagnosis: Early detection improves treatment outcomes and reduces overall healthcare costs.

Technological advancements: AI-enabled imaging, advanced CT scanners, and software solutions are enhancing screening accuracy and workflow efficiency.

Government and healthcare initiatives: National screening guidelines and reimbursement policies are supporting broader adoption.

Market Trends and Opportunities

The integration of artificial intelligence and machine learning into imaging platforms is a major trend, enabling faster image interpretation and reduced false positives. Cloud-based data management and tele-radiology solutions are improving access to screening services, particularly in remote areas. Emerging economies offer strong growth opportunities as healthcare infrastructure improves and awareness of preventive oncology increases.

Get instant access to a free sample report complete with the full TOC.

Competitive Landscape

The lung cancer screening market is moderately competitive, with diagnostic imaging and healthcare technology companies playing a central role. Key players operating in the market include:

Canon Medical Systems

Eon Health

Fujifilm Holdings Corporation

Koninklijke Philips N.V.

Medtronic Plc

Microsoft Corporation (Nuance Communications, Inc.)

Penrad Technologies Inc.

Miltenyi Biotec

Volpara Solutions Limited

General Electric

These companies focus on imaging innovation, AI-driven diagnostics, and strategic collaborations with healthcare providers to strengthen market presence.